Japan's top labour union body says its members seek 6.11% average wage hike

Published on 05/03/2025 at 02:40

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Takeda Pharmaceutical Company Limited

Keros Initiates Dosing in Phase 3 Anemia Trial, Triggering $10 Million Milestone Payment From Takeda	07-17	MT
Sector Update: Health Care Stocks Decline Premarket Monday	07-14	MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday Amid Fresh Tariff Warnings	07-14	MT
Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (Tak-861) in Narcolepsy Type 1	07-14	CI
Takeda Pharmaceutical's Potential Narcolepsy Treatment Meets Endpoints in 2 Studies	07-14	MT
Takeda Pharmaceutical - positive results from two pivotal phase 3 studies of oveporexton (TAK-861) in narcolepsy type 1	07-14	RE
Takeda Completes Treasury Share Disposal Under Overseas Employee Incentive Plan	07-08	MT
US FDA approves KalVista's oral swelling disorder drug, shares rise	07-07	RE
Takeda Pharmaceutical Company Limited Announces U.S. FDA Approval of Gammard Liquid Immunoglobulin Therapy with Low Immunoglobulin A Content	06-30	CI
Takeda Pharmaceutical Receives FDA Approval for Ready-to-Use Liquid Immunoglobulin Therapy	06-30	MT
Takeda Pharmaceuticals Gets FDA Approval for Liquid Gammagard	06-30	DJ
S&P Rates Takeda Pharmaceutical US Unit's Notes BBB+	06-27	MT
Takeda Pharmaceutical Company Limited, 2025 Earnings Call, May 08, 2025	06-26
Takeda Pharmaceutical Company Limited Announces Change in Compensation Committee Members, Effective June 25, 2025	06-25	CI
Takeda Pharmaceutical Company Limited - Special Call	06-10
Keros Therapeutics Shareholder Seeks $475 Million Dividend; Threatens to Nominate New Directors at 2026 Annual Meeting	06-09	MT
Trump's tariffs and threatened trade actions	06-04	RE
Trump's tariffs and threatened trade actions	06-04	RE
European Commission Approves Adcetris®? (Brentuximab Vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage Iib/Iii/Iv Hodgkin Lymphoma in Combination with Ecadd	06-03	CI
Takeda Pharmaceutical Receives European Commission Approval for Adcetris Regimen to Treat Hodgkin Lymphoma	06-03	MT
Takeda to Withdraw, Replace Shelf Registration to Support Incentive Plan	06-03	MT
Takeda Pharmaceutical Says Co Will File Shelf Registration Statement In Japan	06-02	RE
Protagonist Therapeutics, Inc. and Takeda Announce Asco Plenary Presentation Highlighting Full 32-Week Results from Phase 3 Verify Study of Rusfertide	06-02	CI
Protagonist Therapeutics, Takeda's Potential Polycythemia Vera Drug Meets Primary Endpoint	06-02	MT
Takeda Presents Clinical Data of Polycythemia Vera Treatment at Oncology Conference	06-02	MT